Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular pathogenesis of diffuse large B-cell lymphoma.

Izidore S Lossos1

  • 1University of Miami, Sylvester Comprehensive Cancer Center, Department of Hematology and Oncology, 1475 NW 12th Ave (D8-4), Miami, FL 33136, USA. ilossos@med.miami.edu

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|September 13, 2005
PubMed
Summary

Diffuse large B-cell lymphoma (DLBCL) is a complex cancer. Research reveals distinct DLBCL subtypes with unique origins and molecular features, advancing our understanding of its pathogenesis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

American journal of hematology·2026
Same author

Response to: "Refining Combined-Modality Therapy and Charting the Future of Primary Vitreoretinal Lymphoma".

American journal of hematology·2026
Same author

MRD testing in Hodgkin lymphoma: filling the knowledge gaps.

Blood·2026
Same author

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Blood cancer journal·2026
Same author

Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.

Molecular cancer·2026

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) represents a significant portion of non-Hodgkin's lymphomas.
  • The underlying biology and development of DLBCL are known to be complex and varied.

Purpose of the Study:

  • To review recent advancements in understanding DLBCL biology.
  • To provide a comprehensive overview of the molecular pathogenesis of DLBCL.

Main Methods:

  • Analysis of global gene expression using DNA microarrays.
  • Application of classical molecular approaches.
  • Review of current scientific literature.

Main Results:

  • Identification of distinct DLBCL subtypes.

Related Experiment Videos

  • Characterization of subtypes by cell of origin.
  • Elucidation of cytogenetic and molecular aberrations.
  • Understanding of divergent pathogenic pathways.

    • Conclusions:

    • DLBCL is a heterogeneous disease with multiple molecular subtypes.
    • Progress in gene expression and molecular analyses has significantly improved our understanding of DLBCL pathogenesis.
    • Further research into these subtypes is crucial for targeted therapies.